Huyang Xie

Dr. Huyang Xie


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HFHangcheng Fu
Hangcheng Fu
YZYu Zhu
Yu Zhu
YWYiwei Wang
Yiwei Wang
ZLZheng Liu
Zheng Liu
JZJunyu Zhang
Junyu Zhang
JXJiejie Xu
Jiejie Xu
Purpose: This study aims to construct the stromal immunotype, which could improve the prediction of postsurgical survival and adjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC). Experimental Design: A total of 118 patients with MIBC from Shanghai Cancer Center, 140 patients with MIBC from Zhongshan Hospital, and 287 patients with MIBC from TCGA cohort were included in the study. Immune cell infiltration was evaluated by IHC staining or CIBERSORT method. Five immune features were selected out of 22 immune features to construct immunotypes based on the LASSO Cox regression model. Results: Using the LASSO model, we classified patients with MIBC into stromal immunotype A subgroup (CTLhighNKhighTreglowMacrophagelowMClow) and stromal immunotype B subgroup (CTLlowNKlowTreghighMacrophagehighMChigh). Significant differences were found between immunotype A and immunotype B in the combined cohort with 5-year overall survival (OS, 76.0% vs. 44.0%; P < 0.001) and 5-year disease-free survival (DFS, 62.8% vs. 48.3%; P < 0.001). Stromal immunotype was revealed to be an independent prognostic indicator in multivariate analysis in all cohorts separately. Either OS or DFS was not improved by adjuvant chemotherapy (ACT) in pT2 stage patients or pT3+pT4 patients, but further analysis revealed that OS and disease-free was significantly improved by ACT in pT3+pT4 patients (P = 0.016 and P = 0.006, respectively). Finally, stromal immunotype A showed higher immune checkpoint molecules (PD-L1, PD-1, and CTLA-4) expression. Conclusions: The stromal immunotypes could effectively predict survival and recurrence of MIBC. Furthermore, the immunotypes might be a practical predictive tool to identify pT3+pT4 patients who would benefit from ACT. Clin Cancer Res; 24(13); 3069–78. ©2018 AACR.

23 July 2018 in OncoImmunology
Verified
Journal Article
Closed access
ZLZheng Liu
Zheng Liu
YZYu Zhu
Yu Zhu
LXLe Xu
Le Xu
JZJunyu Zhang
Junyu Zhang
HXHuyang Xie
Huyang Xie
JXJiejie Xu
Jiejie Xu
Which subgroups patients with muscle-invasive bladder cancer (MIBC) could benefit most from adjuvant chemotherapy (ACT) is blurred. Here we tried to stratify MIBC patients with tumor infiltrating mast cells (TIMs), explore the prognostic and predictive value of TIMs, and provide possible cellular explanations. We selected 259 MIBC patients who underwent radical cystectomy from two independent clinical centers between 2002 and 2014. TIMs were evaluated and prognostic and predictive value was assessed. The CIBERSORT method, Gene Set Enrichment Analysis (GSEA) and differential gene expression analyses were performed to explore the possible cellular mechanisms. TIMs infiltration was distinct between stromal and epithelial area of MIBC specimens. Patients with higher stromal TIMs had a significant worse overall survival and recurrence free survival (HR = 2.228, 95%CI: 1.467–3.550; P = 0.001 and HR = 1.984, 95%CI: 1.105–3.374; P = 0.016). More importantly, pT2 patients with low stromal TIMs tended to have a lower risk of death and recurrence after ACT (HR = 0.233, 95%CI: 0.020–0.814; P = 0.033 and HR = 0.180, 95%CI: 0.022–0.722; P = 0.031). A negative correlativity between TIMs and CD8 + T cells was identified on TCGA-BLCA cohort. Immunohistochemistry results validated that high stromal TIMs were negatively correlated with CD8 + T cells (Spearman’s rho = -0.215, P < 0.001). Differential gene expression suggested that low TIMs might represent a state of immune activation in MIBC. To conclude, high stromal TIMs infiltration was an independent unfavorable prognosticator for MIBC patients. Patients with low stromal TIMs might benefit the most from ACT, especially in pT2 stage.

29 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FXFujiang Xu
Fujiang Xu
KCKun Chang
Kun Chang
JMJian Ma
Jian Ma
YQYuanyuan Qu
Yuanyuan Qu
HXHuyang Xie
Huyang Xie
DYDing Ye
Ding Ye
Clear cell renal cell carcinoma (ccRCC) is the most common adult renal neoplasm and its incidence continues to increase. Collagen is the most abundant extracellular matrix protein in stroma, and contributes to the development and progression of ccRCC. We examined the human collagen type XXIII α1 chain (COL23A1) expression in ccRCC and the relationship between COL23A1 and patients’ survival. We found COL23A1 mRNA was elevated in tumor compared with adjacent normal tissues, which was further validated by TCGA cohort. IHC results from 151 ccRCC cases suggested that high COL23A1 expression correlated with larger tumor size (P = 0.017) and advanced T stage (P = 0.011). The overall survival (OS) was shorter for ccRCC patients with high COL23A1 expression (P = 0.002). In multivariate analysis, high COL23A1 expression was an independent prognostic factor of OS (HR: 3.024, P = 0.017). Furthermore, COL23A1 knockdown repressed proliferation of ccRCC cell lines by blocking cell cycle progression. Cell adhesion and migration capacity was also downregulated by knockdown of COL23A1. Our data indicate that COL23A1 may be a novel prognostic indicator in ccRCC and might be a specific and accessible biomarker as well as a potential new target for clinical diagnosis of ccRCC.

8 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
ZWZewei Wang
Zewei Wang
HXHuyang Xie
Huyang Xie
LZLin Zhou
Lin Zhou
ZLZheng Liu
Zheng Liu
HFHangcheng Fu
Hangcheng Fu
JXJiejie Xu
Jiejie Xu
CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma

15 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
HXHuyang Xie
Huyang Xie
YZYu Zhu
Yu Zhu
HAHuimin An
Huimin An
HWHongkai Wang
Hongkai Wang
YZYao Zhu
Yao Zhu
DYDing Ye
Ding Ye
Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma

1 September 2012 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
HXHuyang Xie
Huyang Xie
YZYao Zhu
Yao Zhu
XYXu-Dong Yao
Xu-Dong Yao
SZShi-Lin Zhang
Shi-Lin Zhang
BDBo Dai
Bo Dai
DYDing-Wei Ye
Ding-Wei Ye